EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Effectiveness of Bimekizumab in Psoriatic Arthritis: A Multicenter Real‐Life Study With Clinical and Ultrasound Evaluation in the Lazio Region, Italy

Giacomo Caldarola iD, Annunziata Dattola iD, Nicoletta Bernardini iD, Veronica Blundo, Elena Campione iD, Eleonora De Luca iD, Domenico Giordano iD, Alessandro Giunta iD, Gaia Moretta iD, Diego Orsini iD, Gianluca Pagnanelli iD, Antonio Richetta iD und 1 weitere

International Journal of Dermatology · 2025

DOI: 10.1111/ijd.17927 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Dermatology, 2025. Verfasst von Giacomo Caldarola und 12 weiteren Autor:innen. Beteiligte Einrichtung: UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Bimekizumab, a monoclonal antibody targeting interleukin (IL)‐17A and IL‐17F, has shown efficacy in psoriatic arthritis (PsA) clinical trials, but real‐world data on its effectiveness are limited. This study aimed to evaluate its real‐world effectiveness in PsA patients treated in dermatologic settings.

Methods

We conducted a multicenter, prospective, observational study in dermatology units across Lazio, Italy, including 20 patients with psoriasis and PsA treated with bimekizumab. Rheumatologic assessments were performed at baseline and after 16 weeks, evaluating tender and swollen joint counts, the Visual Analog Scale (VAS) pain score, the Disease Activity in Psoriatic Arthritis (DAPSA) score, and the Leeds Enthesitis Index (LEI). Ultrasound evaluations (US) of joints and entheses were conducted at baseline and Week 16.

Results

Twenty patients were enrolled, including 10 bio‐experienced patients. At 16 weeks, significant improvements were observed in tender joint count (3.65 to 2.15, p = 0.004), swollen joint count (1.35 to 0.55, p = 0.028), VAS pain score (6.35 to 3.35, p < 0.001), DAPSA (22.71 to 8.67, p < 0.001), and LEI (0.85 to 0.25, p = 0.004). US revealed a decrease in the number of patients with power Doppler (PD) positive joints (45% to 25%) and a reduction in synovial PD score (2.26 to 0.81, p = 0.002). The number of patients with US‐positive enthesitis decreased (50% to 30%), with a significant reduction in the enthesis PD score (1.00 to 0.25, p = 0.047). Four patients (20%) developed mild candidiasis, with no treatment discontinuation.

Conclusions

Bimekizumab demonstrated significant, rapid improvements in real‐world PsA patients, including those with prior biologic failures. Its favorable safety profile and effectiveness highlight its potential as a valuable treatment option for PsA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, PsoriaticAntibodies, Monoclonal, HumanizedHumansMaleFemaleProspective StudiesMiddle AgedItalyAdultUltrasonographyTreatment OutcomeSeverity of Illness IndexPain MeasurementJointsAged

Stichwörter der Autor:innen

Interleukin‐17bimekizumabbiologic therapiespsoriasispsoriatic arthritisreal‐world effectivenessultrasound

Substanzen

bimekizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy.
  • Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Unit of Dermatology, Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy.
  • Dermatology Unit, ASL LATINA, Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Latina, Italy.
  • Department of Clinical and Molecular Medicine, S. Andrea University Hospital, Sapienza University, Rome, Italy.
  • Department of Systems Medicine, University of Rome 'Tor Vergata', Rome, Italy.

ORCID-Profile: Giacomo Caldarola, Annunziata Dattola, Nicoletta Bernardini, Elena Campione, Eleonora De Luca, Domenico Giordano, Alessandro Giunta, Gaia Moretta, Diego Orsini, Gianluca Pagnanelli, Antonio Richetta, Andrea Picchianti Diamanti

Zitieren

APA

Caldarola, G., Dattola, A., Bernardini, N., Blundo, V., Campione, E., De Luca, E., Giordano, D., Giunta, A., Moretta, G., Orsini, D., Pagnanelli, G., Richetta, A., & Picchianti Diamanti, A. (2025). Effectiveness of Bimekizumab in Psoriatic Arthritis: A Multicenter Real‐Life Study With Clinical and Ultrasound Evaluation in the Lazio Region, Italy. International Journal of Dermatology. https://doi.org/10.1111/ijd.17927

Vancouver

Caldarola G, Dattola A, Bernardini N, Blundo V, Campione E, De Luca E, et al. Effectiveness of Bimekizumab in Psoriatic Arthritis: A Multicenter Real‐Life Study With Clinical and Ultrasound Evaluation in the Lazio Region, Italy. International Journal of Dermatology. 2025. doi:10.1111/ijd.17927

BibTeX
@article{Caldarola2025,
  author = {Caldarola, Giacomo and Dattola, Annunziata and Bernardini, Nicoletta and Blundo, Veronica and Campione, Elena and De Luca, Eleonora and Giordano, Domenico and Giunta, Alessandro and Moretta, Gaia and Orsini, Diego and Pagnanelli, Gianluca and Richetta, Antonio and Picchianti Diamanti, Andrea},
  title = {Effectiveness of Bimekizumab in Psoriatic Arthritis: A Multicenter Real‐Life Study With Clinical and Ultrasound Evaluation in the Lazio Region, Italy},
  journal = {International Journal of Dermatology},
  year = {2025},
  doi = {10.1111/ijd.17927}
}
Kostenlos starten →